Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Factsheets on Biomarkers


The ESMO Translational Research and Precision Medicine Working Group has developed factsheets of validated biomarkers designed to assist you in your daily practice. They give statements on:

  • Prognostic value
  • Predictive value
  • Testing recommendations
  • Ensuring quality and timely testing results
  • Patient selection

A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers are key components of translational studies. Ideally, the development of targeted therapies should be closely coupled with the identification and validation of biomarkers.

ESMO recommends running tumour NGS in advanced non-squamous non-small cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma, ovarian cancer, breast cancer and rare tumours such as gastrointestinal stromal tumours, sarcoma, thyroid cancer, and cancer of unknown primary. ESMO also recommends performing tumour NGS to detect tumour-agnostic alterations in patients with metastatic cancers where access to matched therapies is available.

Filter by:

26 results

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.